Proteomics comparison of the sera from multiple sclerosis patients and neuromyelitis optica patients

Jiang, Shoufeng; Lu, Qun-Qun; Hu, Shoulong; Chen, Y.; Liu, X.L.; Yang, Yi; Ding, Meiping

doi:10.4238/2014.february.14.3

Cited by 13 publications

(19 citation statements)

References 19 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The P43 protein was successfully identified as human haptoglobin. This was similar to the findings that an unknown protein spot identified as haptoglobin in patient sera using the mass spectra strategy (26)(27)(28). For further verification of the mass spectra results, western blotting was used (29), and the results demonstrated that haptoglobin protein was specificity connected with rabbit anti-human-haptoglobin.…”

Section: Discussionsupporting

confidence: 60%

Identification of a protein associated with the activity of cytokine‑induced killer cells

et al. 2017

View full text Add to dashboard Cite

Abstract. Cytokine-induced killer cells (CIKs) adoptive immunotherapy for efficient antitumor ability is used clinically, but details regarding the proteins associated with CIK activity remain unclear. In the current study, the cytotoxicity of CIKs on hepatoma was identified to be significantly downregulated by 1.61-fold following gentamincin treatment. Further research revealed that a differentially expressed protein (P43) was significantly downregulated by 1.22-fold using one-dimensional gel electrophoresis analysis. Of these, the P43 was identified as human haptoglobin using liquid chromatography-mass spectrometry. Western blotting demonstrated that the haptoglobin specifically reacted with rabbit anti-human-haptoglobin. Furthermore, western blotting results verified that the haptoglobin was significantly downregulated by 1.17-fold compared with the control group. In addition, the expression of haptoglobin mRNA was significantly downregulated by 1.73-fold following gentamincin treatment. Taken together, the results of the present study demonstrated that the expression of haptoglobin protein was associated with the activity of CIKs, and the results will be beneficial to the further investigation of CIK activity-enhancement mechanism.

show abstract

Section: Discussionsupporting

confidence: 60%

Identification of a protein associated with the activity of cytokine‑induced killer cells

et al. 2017

View full text Add to dashboard Cite

show abstract

“…This protein was also found lower in MuS CSF in respect to neuromyelitis optica, a disease that is in differential diagnosis with MuS [79]. Moreover, the differences in HP levels were confirmed in serum [80], indicating a diagnostic and prognostic role of this protein to follow MuS patients. In fact the biological fluid in which biomarkers are revealed becomes very important, as biofluid should be easily accessible to allow a closed monitoring disease course and treatment [31].…”

Section: Proteomic Mus Biomarkersmentioning

confidence: 71%

“…Jiang et al. demonstrated that TTR was expressed in MuS CSF and absent in neuromyelitis optica patients , and it seems to modulate during treatment , indicating a prognostic role of this protein. The absence of this protein sounds strange due to its abundance in CSF.…”

Section: Biomarkers For Musmentioning

confidence: 99%

“…The last identified protein possible involved in MuS is the TTR, a very abundant protein in CSF that was found to be modulated in MuS CSF, as shown in Table 2 [107]. Jiang et al demonstrated that TTR was expressed in MuS CSF and absent in neuromyelitis optica patients [80], and it seems to modulate during treatment [108], indicating a prognostic role of this protein. The absence of this protein sounds strange due to its abundance in CSF.…”

Section: Proteomic Mus Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine

Boccio

Rossi

Ioia

et al. 2016

Proteomics Clinical Apps

View full text Add to dashboard Cite

Personalized medicine is the science of individualized prevention and therapy. In the last decade, advances in high-throughput approaches allowed the development of proteomic and metabolomic studies in evaluating the association of genetic and phenotypic variability with disease sensitivity and analgesic response. These considerations have more value in case of multiple sclerosis (MuS), a multifactorial disease with high heterogeneity in clinical course and treatment response. In this review, we reported and updated about proteomic and metabolomic studies for the research of new candidate biomarkers in MuS, and difficulties in their clinical applications. We focused especially on the description of both "omics" approaches that, once integrated, may synergically describe pathophysiology conditions. To prove this assumption, we rebuilt interaction between proteins and metabolites described in the literature as potential biomarkers for MuS, and a pathway analysis of these molecules was performed. The result of such speculation demonstrated a strong convergence of proteomic and metabolomic results in this field, showing also a poorness of available tools for incorporating "omics" approaches. In conclusion, the integration of Metabolomics and Proteomics may allow a more complete characterization of such a heterogeneous disease, providing further insights into personalized healthcare.

show abstract

“…Supplementary Table S1 presents a summary of these data. Beyond metabolomic evaluations of small metabolites, at least eight studies have used MS or NMR platforms to evaluate proteomics in NMOSD [ 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 ] Of these, six studies quantified and compared NMOSD spectral profiles to reference groups [ 134 , 135 , 136 , 137 , 138 , 139 ]. Lee et al 2016 used high resolution hybrid LTQ-orbitrap MS to profile 442 CSF exosome proteins from 10 NMOSD, 12 LETM, and 10 RMMS patients.…”

Section: Proteomics In Nmosdmentioning

confidence: 99%

Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery

Thoman

McKarns

2020

Metabolites

View full text Add to dashboard Cite

There is no specific test for diagnosing neuromyelitis optica spectrum disorder (NMOSD), a disabling autoimmune disease of the central nervous system. Instead, diagnosis relies on ruling out other related disorders with overlapping clinical symptoms. An urgency for NMOSD biomarker discovery is underscored by adverse responses to treatment following misdiagnosis and poor prognosis following the delayed onset of treatment. Pathogenic autoantibiotics that target the water channel aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) contribute to NMOSD pathology. The importance of early diagnosis between AQP4-Ab+ NMOSD, MOG-Ab+ NMOSD, AQP4-Ab− MOG-Ab− NMOSD, and related disorders cannot be overemphasized. Here, we provide a comprehensive data collection and analysis of the currently known metabolomic perturbations and related proteomic outcomes of NMOSD. We highlight short chain fatty acids, lipoproteins, amino acids, and lactate as candidate diagnostic biomarkers. Although the application of metabolomic profiling to individual NMOSD patient care shows promise, more research is needed.

show abstract

Proteomics comparison of the sera from multiple sclerosis patients and neuromyelitis optica patients

Cited by 13 publications

References 19 publications

Identification of a protein associated with the activity of cytokine‑induced killer cells

Identification of a protein associated with the activity of cytokine‑induced killer cells

Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine

Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery

Contact Info

Product

Resources

About